Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Revive Therapeutics Ltd. C.RVV

Alternate Symbol(s):  RVVTF

Healthcare
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. The Company’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the Company was granted Food and Drug Administration (FDA) orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.


CSE:RVV - Post by User

Revive Therapeutics Ltd. > FDA advisers to review Merck's oral COVID-19 drug next month
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(42)
•••
Comment by cool888on Oct 14, 2021 8:48pm
109 Views
Post# 34007595

RE:FDA advisers to review Merck's oral COVID-19 drug next month

RE:FDA advisers to review Merck's oral COVID-19 drug next month
[/quote

I just went to refer the above link, unable to find it on website,  you know why?
As everyone knows, Big Pharma controls everything ... PRICELESS !! Not your life that matters !!

Merck is desparate to be the FIRST, but, have big tome safety issues.

Let's hope Revive beats all A**holes !! with their Safety & Efficacy !!

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities